Bloomios (Bloomios) Risk Assessment

View and export this data going back to 2003. Start your Free Trial

What is Bloomios Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bloomios is: No Data: Cannot be evaluated.

Competitive Comparison of Bloomios's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bloomios's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bloomios's Risk Assessment falls into.

Bloomios (OTCPK:BLMS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bloomios Risk Assessment Related Terms

Thank you for viewing the detailed overview of Bloomios's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Bloomios (Bloomios) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101

Website

https://www.bloomios.com

Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.

Executives

Douglas S Rohrer	officer: Chief Business Officer	701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc	10 percent owner	201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans	director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam	10 percent owner	104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile	10 percent owner	12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc	10 percent owner	201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc	10 percent owner	1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill	director, 10 percent owner, officer: Chief Executive Officer	201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass	director, 10 percent owner, officer: President and Director	20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd	director, officer: Chairman of the Board	8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn	director, officer: President & CEO	13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll	director, 10 percent owner
Van Laare Derek R	officer: Secretary	6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli	other: former director/officer/owner	111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson	director, officer: President & Treasurer	15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000